Bristol Myers Squibb Merges Research and Development Units
The drugmaker is combining its research and development divisions under its chief medical officer, effective January 1.
Updated on Nov. 12, 2026 in Biotech

Live Poll
Do you trust big drugmakers to deliver better medicines for patients?
Bristol Myers Squibb is merging its research and development divisions into one unit led by Cristian Massacesi, its chief medical officer and head of development. A former chief research officer at a major drugmaker has departed the company, and his advisory role ends in March.
Why it matters
BMS CEO Christopher Boerner said traditional boundaries between research and development are collapsing, and the restructuring is intended to speed decision-making and connect scientific and clinical expertise. The company's headcount fell from 34,100 at the end of 2023 to 32,500 at the end of 2025, and the change follows a structure it adopted after its 2019 takeover of Celgene.
Company headcount declined by 1,600 people between the end of 2023 and the end of 2025, while about 8,000 employees worked in R&D groups in 2023. The reported figures do not indicate how the merger will change R&D staffing levels.
The players
Bristol Myers Squibb
A global biopharmaceutical company headquartered in New York that develops and sells prescription medicines across oncology, immunology and cardiovascular disease.
Cristian Massacesi
The chief medical officer and head of development at Bristol Myers Squibb who will lead the combined research and development unit.
Christopher Boerner
The chief executive officer of Bristol Myers Squibb who described the restructuring as a response to converging research and development work.
The details
Under the new structure, Cristian Massacesi will lead a combined research and development unit as head of R&D, with the change taking effect January 1. The company's major R&D sites are in California, Massachusetts and New Jersey, and peers including Eli Lilly, Merck & Co. and Pfizer already have leaders overseeing both functions.
Timeline
2019: BMS adopted its prior R&D structure after acquiring Celgene.
Late October 2026: CEO Christopher Boerner discussed R&D productivity on the third-quarter earnings call.
January 1, 2027: Massacesi begins leading the combined R&D unit.
March 2027: The former chief research officer's advisory role with BMS ends.
Roadmap
The merger reverses the research and development separation BMS adopted after its 2019 takeover of Celgene. It follows a model already used by Eli Lilly, Merck & Co. and Pfizer, which have leaders overseeing both research and development within one division.
The restructuring is an internal corporate change and does not directly alter how patients obtain existing BMS medicines. Its effect on new drug development timelines has not been reported.
The takeaway
Corporate reorganizations in drug development often signal how companies plan to move candidates from lab to clinic. Readers following pharmaceutical pipelines can watch whether combined leadership changes BMS's development output in coming quarters.
What happens next
The combined research and development organization takes effect January 1, 2027, and the former chief research officer's advisory role ends in March 2027.
Further reading
Explore more Biotech coverage for context on how drugmakers are organizing their research pipelines.
Live Poll
Do you trust big drugmakers to deliver better medicines for patients?






